In male patients with KRAS-mutant CRC, decreased ferritin activity has also been observed, suggesting that these tumors may depend on mitochondrial redox-buffering mechanisms to evade iron-dependent cytotoxic responses [5, 72, 73]. The gene discussed is KRAS; the disease is colorectal carcinoma.